YouTube · Q2 2026 · 2026-07-21
TMO · NYSE
Thermo Fisher Scientific
Diagnostics & Research · United States
- Market cap (USD)
- US$240.87B
- Trailing P/E
- 35.08x
- Forward P/E
- 23.66x
- Quarterly revenue growth
- 10.5%
- Trailing net margin
- 15.0%
- Indicated dividend yield
- 0.3%
Snapshot 2026-09-20 · Latest financial period 2026-06-27 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-21 (provider estimate, not issuer-confirmed).
Company background
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Company websiteQ2 2026
Go beyond the headline.
Comparable businesses
TMO peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | TMOThermo Fisher Scientific Inc.Snapshot 2026-09-20Financial period: 2026-06-27 | DHRDanaher CorporationSnapshot 2026-09-20Financial period: 2026-06-26 | IQVIQVIA Holdings Inc.Snapshot 2026-09-20Financial period: 2026-06-30 |
|---|---|---|---|
| Market capMarket value, converted to USD | US$240.87B | US$148.90B | US$43.85B |
| Forward P/EProvider forward earnings estimate | 23.66x | 22.78x | 18.43x |
| EV / EBITDAEnterprise value / trailing EBITDA | 23.81x | 21.48x | 19.08x |
| Revenue growthLatest quarter vs prior-year quarter | 10.5% | 5.5% | 8.7% |
| Operating marginLatest reported quarter | 18.8% | 19.8% | 13.0% |
| Free cash flow yieldTrailing cash flow / market cap | 2.6% | 2.9% | 4.9% |
| Net debt / EBITDANet debt / trailing EBITDA | 3.28x | 2.93x | 4.65x |
| Debt / equityTotal debt / positive book equity | 0.81x | 0.53x | 2.58x |
| Trailing P/ETrailing twelve-month earnings | 35.08x | 37.76x | 33.10x |
| Price / bookPrice / positive book equity per share | 4.57x | 2.83x | 7.11x |
| EV / salesEnterprise value / trailing revenue | 6.03x | 6.87x | 3.42x |
| Earnings growthLatest quarter vs prior-year quarter | 9.4% | 59.7% | -0.6% |
| Gross marginTrailing twelve months | 41.0% | 58.8% | 33.0% |
| Net marginTrailing twelve months | 15.0% | 15.9% | 8.1% |
| Return on equityProvider trailing return; positive equity only | 13.5% | 7.6% | 22.8% |
| Free cash flow marginTrailing free cash flow / revenue | 13.5% | 17.2% | 12.7% |
| Dividend yieldIndicated annual dividend / price | 0.3% | 0.8% | — |
| Earnings payoutProvider trailing dividend payout | 9.7% | 25.7% | 0.0% |
| Current ratioCurrent assets / current liabilities | 1.55x | 1.65x | 0.71x |
| BetaProvider historical market sensitivity | 0.85 | 0.81 | 1.19 |
YouTube · Q2 2026 · 2026-07-21
YouTube · Q2 2026 · 2026-08-02
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-09-20. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for TMO
Q2 20262026-07-23
Thermo Fisher Stock (TMO): Beat Earnings, Margins Up, Down 31% — Why We Say BUY
Presentation · 2026-07-23 · YouTube
Q4 20252026-04-13
Charged Alpha | Thermo Fisher Scientific (TMO) | Q4 2025 Earnings Deep Dive — Ep. 109
Presentation · 2026-04-13 · YouTube
Q1 2026
TMO Q1 2026 earnings analysis · No verified episode link yet.